Balchem (BCPC) to Release Quarterly Earnings on Thursday

Balchem (NASDAQ:BCPC) is expected to release its Q2 2025 earnings data before the market opens on Thursday, July 31st. Analysts expect Balchem to post earnings of $1.25 per share and revenue of $250.31 million for the quarter.

Balchem Stock Up 1.4%

Shares of NASDAQ:BCPC opened at $152.75 on Wednesday. The stock has a market cap of $4.98 billion, a price-to-earnings ratio of 36.63, a PEG ratio of 3.25 and a beta of 0.89. The company has a quick ratio of 1.40, a current ratio of 2.44 and a debt-to-equity ratio of 0.18. Balchem has a 12-month low of $145.70 and a 12-month high of $185.96. The business’s 50 day moving average is $161.27 and its 200 day moving average is $162.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BCPC. Advisors Asset Management Inc. purchased a new position in Balchem in the first quarter worth $27,000. AQR Capital Management LLC boosted its position in Balchem by 124.4% in the first quarter. AQR Capital Management LLC now owns 5,074 shares of the basic materials company’s stock worth $842,000 after purchasing an additional 2,813 shares during the last quarter. Jones Financial Companies Lllp boosted its position in Balchem by 1,768.2% in the first quarter. Jones Financial Companies Lllp now owns 822 shares of the basic materials company’s stock worth $136,000 after purchasing an additional 778 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Balchem by 53.6% in the first quarter. Goldman Sachs Group Inc. now owns 246,883 shares of the basic materials company’s stock worth $40,983,000 after purchasing an additional 86,132 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Balchem by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 100,860 shares of the basic materials company’s stock worth $16,743,000 after purchasing an additional 9,118 shares during the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BCPC. HC Wainwright set a $180.00 target price on Balchem and gave the company a “buy” rating in a research report on Monday, April 28th. Wall Street Zen cut Balchem from a “buy” rating to a “hold” rating in a research report on Saturday.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.